All In Biotech

Drug Trial Radar · NCT07938463

Lorlatinib Plus TNG462 in ALK+ MTAP Del NSCLC

TAP-ALK: A Phase I/II Study of TNG462 in Combination With Lorlatinib in MTAP-Deleted, ALK-Rearranged NSCLC Following Progression on Prior TKI Therapy

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Apr 30, 2027

Primary completion

Nov 30, 2027

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Dana-Farber Cancer InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Tango Therapeutics, Inc.; ALK Positive / ALK Positive Patients Association
First posted
Nov 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TAP-ALK is a DF/HCC investigator-sponsored interventional study of TNG462 (vopimetostat) in combination with lorlatinib for participants with MTAP-deleted, ALK-rearranged non-small cell lung cancer (NSCLC) following progression on prior tyrosine kinase inhibitor (TKI) therapy. The study is being conducted under IND 183798 and plans to enroll 30 participants.

Conditions

  • ALK Positive Non-small Cell Lung Cancer

Interventions

  • TNG462 vopimetostatDrug

    Investigational drug Supplier/manufacturer: Tango Therapeutics

  • LorlatinibDrug

    Source/manufacturer: Commercial supply / Pfizer

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experience Dose-Limiting Toxicity (DLT)Time frame: Up to 28 days.
  2. Maximum Tolerated Dose (MTD) of TNG462Time frame: Up to 28 days.
  3. MTD of LorlatinibTime frame: Up to 28 days.
  4. Recommended Phase II Dose (RP2D) of TNG462 in Combination with LorlatinibTime frame: Up to 28 days.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.